PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novel Classes to Drive Growth in Major European Oral Antidiabetic Markets - New studies on major European diabetes markets released by IMARC Group suggests that Novel classes will drive the growth of the Oral Antidiabetic markets in the coming years - IMARCgroup.com
Novel Classes to Drive Growth in Major European Oral Antidiabetic Markets

 

NewswireToday - /newswire/ - Delhi, India, 2011/04/14 - New studies on major European diabetes markets released by IMARC Group suggests that Novel classes will drive the growth of the Oral Antidiabetic markets in the coming years - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In its new therapy area insight series - Diabetes, IMARC Group, one of the world’s leading research and advisory firms, finds that Novel classes such as DPP-IV Inhibitors, GLP-Agonists and SGLT inhibitors will play a major role in driving the growth of major European Oral Antidiabetic markets. Findings from the reports suggest that in the next few years these classes will show a strong uptake both as a monotherapy and also as a combination with traditional Oral Antidiabetic classes such as Glitazones and Biguanides. According to the study, novel classes will account for more than half of the total Oral Antidiabetic sales in major European markets by 2016.

IMARCS’s global therapy area insight series includes the following reports:

• France Diabetes Market Forecast 2011-2016
• Italy Diabetes Market Forecast 2011-2016
• Germany Diabetes Market Forecast 2011-2016
• Spain Diabetes Market Forecast 2011-2016
• United Kingdom Diabetes Market Forecast 2011-2016

Each of these reports provide an analytical and statistical insight into their respective diabetes markets. The current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes have been thoroughly analyzed in each of these reports. The study has segmented the diabetes market into two categories - Insulin and the Oral Antidiabetics market. For each of the aforementioned cateogories, historical and future market sales of key classes, key companies, key drugs and key molecules have been provided.

The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the diabetes market till 2016. These reports can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the European diabetes market in some form or the other.

Key Questions Answered in this Report:

• What is the size and demographical breakup of the diabetes population?
• What are the current and future diagnosis and drug treatment rates of diabetes?
• How has the diabetes market behaved since 2005 and what are the expected trends till 2016?
• What has been the historical performance of the Insulin market during 2005-2010 and its outlook till 2016?
• What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during 2005-2010?
• What has been the historical performance of the Oral Antidiabetics market during 2005-2010 and its outlook till 2016?
• What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during 2005-2010?

Why should you buy this report?
• Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes and identify your potential patient pool.
• Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics market to identify potential classes, drugs, partners and competitors for market entry and expansion plans.
• Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Insulin and Oral Antidiabetics market.
• Gain an insight into future market events such as biosimilars and new product launches.

Classes Covered:
Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediate acting Insulins, Biguanides, Glitazone and Biguanide combinations, Biguanide and Sulphonylurea combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide combinations, DPP-IV Inhibitor and Glitazone combinations, Glitazone and Sulphonylurea combinations, SGLT Inhibitors, SGLT Inhibitor and Biguanide combinations, PTP1B Inhibitors and all other Oral Antidiabetic classes.

Information Sources:

Information has been gathered from both primary and secondary sources:
• Primary sources include industry surveys and face to face/telephone interviews with physicians and industry experts.
• Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases.

Forecasting Methodology:
IMARC (imarcgroup.com) generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast.

Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America) or email sales[.]imarcgroup.com or visit imarcgroup.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novel Classes to Drive Growth in Major European Oral Antidiabetic Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  1Click Games

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)